Aldahan Zahra, Kim Jiwon, Yoon Chul Young, Seo Young Joon, Park Kyoung Ho
Department of Otolaryngology-Head & Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Research Institute of Hearing Enhancement, Yonsei University Wonju College of Medicine, Wonju, Korea.
J Audiol Otol. 2025 Apr;29(2):110-116. doi: 10.7874/jao.2024.00493. Epub 2025 Apr 18.
Certain medications are associated with ototoxicity. This study assesses drug-induced ototoxicity in South Korea by analyzing the Korean national health data.
Hospital records of National Health Insurance members from 2009 to 2016 were reviewed. Data were compared between patients with and without hearing loss (HL). Individuals with HL were identified as having a primary diagnosis code for sensorineural HL or another type of HL in at least one outpatient or inpatient record according to the International Classification of Diseases-10.
The members in the HL group increased slightly from 0.8% to 1.0% relative to the total sample, compared with 99.2% to 99.0% among the controls. The proportion of males in the HL group ranged from 45.6% to 47.6%, compared with 48.4% to 48.8% among the controls. The proportion of those aged ≥65 years in the HL group increased from 34.1% to 41.4%, compared with 10.6% to 13.3% among the controls. Hypertension prevalence (24.7%-25.7%) in the HL group was higher than that in the control group (12%-12.6%). Diabetes prevalence in the HL group was 10.6%-12.3%, compared with 4.4%-5.9% among the controls. The use of proton pump inhibitor components increased, particularly esomeprazole magnesium trihydrate and rabeprazole sodium, whereas the usage of pantoprazole sodium sesquihydrate and revaprazan was high initially but declined subsequently. The usage of painkillers such as acetaminophen, loxoprofen sodium, and ibuprofen remained high, and antibiotics such as cephalosporins indicated the highest usage. However, the use of penicillin antibiotics such as amoxicillin decreased significantly. Anticancer agents showed relatively low usage compared with other drug categories, whereas antihistamines showed extremely high usage across all years, with a continual increase.
These correlations and the underlying mechanisms necessitate further investigation, as several medicines have been linked to an increased risk of HL.
某些药物与耳毒性有关。本研究通过分析韩国国家健康数据评估韩国药物性耳毒性情况。
回顾了2009年至2016年国民健康保险参保人员的医院记录。对有听力损失(HL)和无听力损失的患者数据进行了比较。根据国际疾病分类第10版,HL患者被确定为在至少一份门诊或住院记录中有感音神经性HL或其他类型HL的主要诊断代码。
HL组成员相对于总样本略有增加,从0.8%增至1.0%,而对照组从99.2%降至99.0%。HL组男性比例在45.6%至47.6%之间,而对照组在48.4%至48.8%之间。HL组中≥65岁者的比例从34.1%增至41.4%,而对照组在10.6%至13.3%之间。HL组高血压患病率(24.7% - 25.7%)高于对照组(12% - 12.6%)。HL组糖尿病患病率为10.6% - 12.3%,而对照组为4.4% - 5.9%。质子泵抑制剂成分的使用增加,尤其是三水合埃索美拉唑镁和雷贝拉唑钠,而泮托拉唑钠倍半水合物和瑞伐拉唑最初使用量高但随后下降。对乙酰氨基酚、洛索洛芬钠和布洛芬等止痛药的使用量仍然很高头抱菌素类等抗生素的使用量最高。然而,阿莫西林等青霉素类抗生素的使用量显著下降。与其他药物类别相比,抗癌药的使用量相对较低,而抗组胺药在所有年份的使用量都极高且持续增加。
由于几种药物与HL风险增加有关,这些相关性及潜在机制需要进一步研究。